Antihypertensive drug

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

Retrieved on: 
Thursday, July 1, 2021
Organic compounds, Chemical compounds, Chemistry, Chloroarenes, Amines, Amlodipine, Dihydropyridines, Ethers, Indapamide, Angiotensin II receptor blocker, Hypertension, Antihypertensive drug

London, UK, 1 July 2021 George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the worlds leading causes of death, today announces the initiation of two Phase III trials investigating its proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.

Key Points: 
  • London, UK, 1 July 2021 George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the worlds leading causes of death, today announces the initiation of two Phase III trials investigating its proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.
  • GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
  • Fewer than one in five people with hypertension have the problem under control.3
    The Phase III trials follow successful earlier trials of a low dose triple combination which significantly outperformed traditional high blood pressure treatments without additional side effects.
  • Prof Dr Anthony Rodgers, Chief Scientific Officer of George Medicines, said: We are very pleased to be starting these two Phase III trials.

CureApp and Jichi Medical University Collaborate on a Hypertension Therapeutics App: Primary Endpoint Met in Phase III Clinical Trial in Japan

Retrieved on: 
Thursday, March 18, 2021
Technology, Mobile, Wireless, Clinical trials, Cardiology, Software, Health, University, General Health, Education, Hypertension, Health, Behavior modification, Digital therapeutics, Medicine, Antihypertensive drug, Clinical endpoint, Essential hypertension

Results of this study showed a statistically significant difference in average systolic blood pressure*1 over a 24-hour period the primary endpoint of this study, demonstrating a hypotensive effect.

Key Points: 
  • Results of this study showed a statistically significant difference in average systolic blood pressure*1 over a 24-hour period the primary endpoint of this study, demonstrating a hypotensive effect.
  • View the full release here: https://www.businesswire.com/news/home/20210318005504/en/
    CureApp and Jichi Medical University collaborate on a hypertension therapeutics app: Primary endpoint met in Phase III clinical trial in Japan (Graphic: Business Wire)
    Commencing in December 2019, this trial*2 evaluated the efficacy and safety of the DTx app when used with patients with essential hypertension who had not received oral treatments using antihypertensive drugs.
  • In Japan, hypertension is found in some 43 million people*3, and medical costs associated with hypertension have ballooned to around 1.7 trillion yen*6.
  • A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial.

CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects

Retrieved on: 
Tuesday, October 20, 2020
Clinical medicine, Adrenal gland disorders, Medicine, Antihypertensive drug, Hypertension, Medical specialties, Aldosterone synthase, Primary aldosteronism, Secondary hypertension

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study.

Key Points: 
  • CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study.
  • The brigHTN study is a Phase 2 clinical trial evaluating the blood pressure lowering effects of CIN-107, a novel, once daily, and highly selective aldosterone synthase inhibitor (ASI) in subjects with treatment resistant hypertension.
  • CIN-107 is currently being developed for both treatment resistant hypertension and primary aldosteronism (PA).
  • CIN-107 represents a new class of anti-hypertensive agents that has the possibility of providing significant anti-hypertensive effects to treatment resistant patients, as well as to the broader hypertensive population.

BERG's Study Provides Biological Insights Into The Increased Incidence Of COVID-19 In The African American Population

Retrieved on: 
Wednesday, September 9, 2020
ACE inhibitor, Angiotensin-converting enzyme, Coronavirus disease, Medical specialties, Branches of biology, Organ systems, Angiotensin II receptor blocker, Antihypertensive drug

The study, published today in the Journal of Racial and Ethnic Health Disparities, highlights the increased frequency of an ACE deletion polymorphism in the African American population.

Key Points: 
  • The study, published today in the Journal of Racial and Ethnic Health Disparities, highlights the increased frequency of an ACE deletion polymorphism in the African American population.
  • This genetic aberration has a known association with risk of greater susceptibility to lung and kidney dysfunction, both underlying risk factors for COVID-19 infection, outcomes and increased fatality.
  • Results indicate a strong rationale for the use of ACE inhibitors (ACE-I) and ARBs (AT1 receptor blockers) as treatment intervention to mitigate serious complications in COVID-19 patients.
  • The significant genetic, scientific and clinical data provides a compelling argument for the use of ACE-I and ARBs in the clinical management of patients with COVID-19 infections to improve outcomes.

New Real-World Data from Medtronic Global SYMPLICITY Registry Show Renal Denervation Lowered Blood Pressure in Patients with Hypertension Out to Three Years

Retrieved on: 
Thursday, June 25, 2020
Cardiovascular system, Medicine, Circulatory system, Renal sympathetic denervation, Hypertension, Antihypertensive drug, Orthostatic hypertension, Hypertensive encephalopathy

The number of patients at the very highest BP level greater than 180 mmHg systolic at baseline dropped by two-thirds at three years.

Key Points: 
  • The number of patients at the very highest BP level greater than 180 mmHg systolic at baseline dropped by two-thirds at three years.
  • The BP drops occurred while patients were prescribed an average of four or more anti-hypertensive medications, which remained unchanged over three years.
  • The Global SYMPLICITY Registry is the largest study documenting the long-term safety and effectiveness of the Medtronic renal denervation systems in a real-world setting in patients with uncontrolled hypertension.
  • To date, the registry has enrolled more than 2,860 patients treated with RDN and includes three-year follow-up for more than 2,500 patients.

Study Finds Seniors with COVID-19 Taking Hypertension Medication at Lower Risk of Hospitalization, Clinical Trial to Follow Immediately

Retrieved on: 
Tuesday, May 19, 2020
Insurance, Technology, University, Practice Management, Pharmaceutical, Education, Managed care, Professional services, Seniors, Infectious diseases, Hospitals, Clinical trials, Biotechnology, Software, Consumer, Health, ACE inhibitors, Enzymes, Drugs, RTT, Branches of biology, Prodrugs, Angiotensin-converting enzyme, Hypertension, Atenolol, Antihypertensive drug

A study completed by UnitedHealth Group (NYSE: UNH) with the Yale School of Medicine found that older COVID-19 patients with hypertension taking angiotensin-converting enzyme (ACE) inhibitors had a lower risk of COVID-19 hospitalization.

Key Points: 
  • A study completed by UnitedHealth Group (NYSE: UNH) with the Yale School of Medicine found that older COVID-19 patients with hypertension taking angiotensin-converting enzyme (ACE) inhibitors had a lower risk of COVID-19 hospitalization.
  • A pragmatic clinical trial will be a critical next step.
  • The use of ACE inhibitors was associated with an almost 40% lower risk of COVID-19 hospitalization for Medicare Advantage patients.
  • Use of the medication was not found to reduce mortality risk in individuals once hospitalized with COVID-19.

Insights on the Worldwide Antihypertensive Drugs Industry to 2026 - Players Include Pfizer, Takeda Pharmaceutical & AstraZeneca Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020
Health, Pharmaceutical, Antihypertensive agents, Beta blocker, Antihypertensive drug, Hypertension, Calcium channel blocker, Cardiovascular system, Circulatory system, Medicine

The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.

Key Points: 
  • The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.
  • Antihypertensive drugs are employed for the treatment of patients suffering from hypertension.
  • Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs.
  • Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators.

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

Retrieved on: 
Sunday, March 29, 2020
Hypertension, Medicine, Medical specialties, Cardiovascular system, Renal sympathetic denervation, Denervation, Cardiovascular disease, Antihypertensive drug

The prospectively powered study of patients with uncontrolled high blood pressure (BP) not taking anti-hypertensive medications met itsprimary and secondary effectiveness endpoints, with a >99.9% probability of superiority for both versus those who received a sham control procedure.

Key Points: 
  • The prospectively powered study of patients with uncontrolled high blood pressure (BP) not taking anti-hypertensive medications met itsprimary and secondary effectiveness endpoints, with a >99.9% probability of superiority for both versus those who received a sham control procedure.
  • Blood pressure reductions were sustained consistently throughout the day and nighttime periods, which may offer an important benefit as cardiovascular risk is higher during the nighttime period.
  • Medtronic also recently received Breakthrough Device Designation by the FDA for the Symplicity Spyral renal denervation system.
  • The SPYRAL HTN-OFF MED Pivotal Trial is part of the SPYRAL HTN Global Clinical Trial Program and accompanies the SPYRAL HTN-ON MED Trial and the SPYRAL DYSTAL Study.

Antihypertensive Drugs Market to Garner $28.79 Bn, Globally, by 2026 at 3.1% CAGR, Says Allied Market Research

Retrieved on: 
Wednesday, January 15, 2020
Antihypertensive agents, Blood pressure, Hypertension, Antihypertensive drug, Medicine, Clinical medicine, Medical specialties

According to the report, the global antihypertensive drugs industry was pegged at $22.56 billion in 2018 and is projected to reach $28.79 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026.

Key Points: 
  • According to the report, the global antihypertensive drugs industry was pegged at $22.56 billion in 2018 and is projected to reach $28.79 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026.
  • Rise in the geriatric population, surge in healthcare expenditure, and rise in prevalence of hypertension across the globe drive the growth of the global antihypertensive drugs market.
  • However, the calcium channel blockers segment held the largest share in 2018, contributing to more than one-fourth of the global antihypertensive drugs market, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs.
  • The global antihypertensive drugs market across North America held the largest share in 2018, accounting for more than one-third of the market, owing to the availability of the antihypertensive drugs and rise in prevalence of hypertension due to surge in geriatric population in the region.

Antihypertensive Drugs Market to Garner $28.79 Bn, Globally, by 2026 at 3.1% CAGR, Says Allied Market Research

Retrieved on: 
Wednesday, January 15, 2020
Antihypertensive agents, Blood pressure, Hypertension, Antihypertensive drug, Medicine, Clinical medicine, Medical specialties

According to the report, the global antihypertensive drugs industry was pegged at $22.56 billion in 2018 and is projected to reach $28.79 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026.

Key Points: 
  • According to the report, the global antihypertensive drugs industry was pegged at $22.56 billion in 2018 and is projected to reach $28.79 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026.
  • Rise in the geriatric population, surge in healthcare expenditure, and rise in prevalence of hypertension across the globe drive the growth of the global antihypertensive drugs market.
  • However, the calcium channel blockers segment held the largest share in 2018, contributing to more than one-fourth of the global antihypertensive drugs market, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs.
  • The global antihypertensive drugs market across North America held the largest share in 2018, accounting for more than one-third of the market, owing to the availability of the antihypertensive drugs and rise in prevalence of hypertension due to surge in geriatric population in the region.